Vivos Therapeutics (NASDAQ: VVOS) is a revenue-stage medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults. The company today announced its entry into an exclusive agreement with GM Instruments Ltd. for the distribution of GM Instruments’ NR6 Rhinomanometer, the only FDA approved four-phase rhinomanometer available in the U.S. used to calculate nasal airway resistance by measuring nasal flow as well as the pressure producing that flow. “With this new agreement, every U.S. or Canadian dentist who wishes to evaluate the breathing function of a patient will need to engage with Vivos for this diagnostic equipment,” said Vivos chairman and CEO Kirk Huntsman. “We expect this will provide Vivos an immediate new revenue stream as well as a substantial competitive advantage and opportunity to present Vivos’ proprietary oral appliance technology to a wider audience.”
To view the full press release, visit https://ibn.fm/GPK1S
About Vivos Therapeutics Inc.
Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults. The company’s Vivos Method represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution and has proven effective in approximately 27,000 patients treated worldwide by more than 1,500 trained dentists. The Vivos Method includes the Vivos Complete Airway Repositioning and/or Expansion (“CARE”) appliance therapy and associated protocols that alter the size, shape and position of the tissues that comprise a patient’s upper airway. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild to moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for Home Sleep Testing in adults and children as well as GM Instruments’ NR6 Rhinomanometer, the only FDA approved 4-phase rhinomanometer available in the U.S. The Vivos Integrated Practice (“VIP”) program offers dentists training and other value-added services in connection with using The Vivos Method. For more information, visit www.Vivos.com.
NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
InvestorWire is part of the InvestorBrandNetwork.